drugset / Trial / NCT04454567
A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will explore the safety and antiviral activity of ABI-H0731 when added to a nucleos(t)ide reverse transcriptase inhibitor (NrtI) in participants who are partially virologically suppressed.
Timeline
- Start
- 2020-11-11
- Primary completion
- 2021-04-08
- Completion
- 2021-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vebicorvir | Small molecule | 300 mg | Oral |
| Background | Entecavir | Small molecule | — | — |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Background | tenofovir alafenamide | Small molecule | — | — |